Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

about

Nanotherapeutics for multiple myeloma.Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens

P2860

Q52559684-48C5365D-2188-4873-83C8-B1B09193816E Q55397591-6393036E-A154-40A6-A5BB-1464CF6EE24A Q58572512-B95FA937-412A-49A4-AF48-002EBC7520F4

P2860

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Item

http://www.wikidata.org/entity/Q47734632

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@en

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@nl

type

Item

label

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@en

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@nl

prefLabel

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@en

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@nl

P1476

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

@en

P2093

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Ioannis Ntanasis-Stathopoulos

http://www.w3.org/2001/XMLSchema#string

Maria Gavriatopoulou

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

WNT signaling in bone homeostasis and disease: from human mutations to treatments

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

Osteoclast differentiation and activation

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

P2888

s41408-017-0037-4

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/S41408-017-0037-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P5008

ScienceSource

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29330358

http://www.w3.org/2001/XMLSchema#string

P921

multiple myeloma

neoplasm proteins

Achyolli

P932

5802524

http://www.w3.org/2001/XMLSchema#string

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

about

P2860

P2860

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932